Experimental drug aims to supercharge immune system before cancer surgery
NCT ID NCT03336606
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a single dose of an experimental antibody (MEDI0562) given before surgery to 13 patients with advanced head and neck cancer or melanoma. The goal was to see if the drug safely activates the immune system to fight the cancer. Researchers compared giving the dose all at once versus splitting it over three days.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, SQUAMOUS CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Can new drug cocktails reawaken the immune system against melanoma?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- Can tailored nutrition boost recovery from head and neck surgery?